SOLIACS: Solian Solution in the Acute Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245674|
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : April 10, 2008
During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.
The main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: amisulpride||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Solian Solution to Treat Schizophrenic Patients During an Acute Episode|
|Study Start Date :||June 2005|
- *analyze the antipsychotic efficacy of amisulpride solution in the first days of an acute schizophrenic episode.
- *analyse the safety profile of amisulpride solution in treatment of schizophrenics with an an acute episode.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245674
|Study Director:||Dr. Christian Fassotte, M.D.||Sanofi|